Currently, two IL-8 targeting antibodies, ABX-CXCL8 and HuMax-CXCL8, are being used in preclinical studies including patients with severe bronchitis and chronic obstructive pulmonary disease (COPD) (NCT00035828) as well as patients with advanced malignant solid tumors (NCT02536469; NCT03689699) (72). Here, CXCL8 is linked to chronic obstructive pulmonary disease.